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Background/aim: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood and manifests mainly as
autoinflammation of the joints and other tissues. Several treatment options such as nonsteroidal antiinflammatory drugs, methotrexate,
and intra-articular steroids are widely used to relieve and improve this inflammation. Secondary carnitine deficiency can be detected in
chronic diseases by either renal loss or increased demand. While carnitine status can be associated with several conditions, in the present
study our aim is to determine the levels of free carnitine and acyl-carnitine in Turkish JIA patients.
Materials and methods: One hundred and fourteen patients diagnosed with juvenile idiopathic arthritis and 50 healthy individuals
who served as the control group were included in the study. A fasting blood sample was collected from the children in both groups to
determine free carnitine and acylcarnitine ester by quadripole electrospray tandem mass spectrometry (ESI-MS/ MS).
Results: Screening of acyl-carnitine profile revealed free carnitine, C14, C14:2, C16, C16-OH, and C18 carnitine levels were higher (p
< 0.0001, p < 0.0001, p < 0.001, p < 0.001, and p = 0.011, respectively), while C2, C3, C4, C6, C8, C10, C10:1, C10:2, C3DC, C4DC,
C5DC, C4-OH, and C18:1-OH carnitine levels were lower (p < 0.0001) in JIA patients in comparison to the control group. Total acylcarnitine levels (p < 0.001) and acyl-carnitine to free carnitine ratio (p < 0.001) were also lower in JIA patients than the control group.
Free carnitine levels were significantly higher (48.05 ± 13.36 μmol/L) in patients under antiinflammatory drug therapy than those who
did not receive any treatment (43.18 ± 7.96 μmol/L) (p = 0.004).
Conclusion: In the present study we were not able to define secondary carnitine deficiency in JIA patients, although free carnitine and
acyl-carnitine variations were detected in JIA patients. In conclusion, routine carnitine supplementation is not recommended in all
patients with JIA.
Key words: Autoinflammation, carnitine deficiency, juvenile idiopathic arthritis, fatty acid metabolism

1. Introduction
Juvenile idiopathic arthritis (JIA) consists of all arthritis
without a known etiology, starting before 16 years of
age and lasting at least 6 weeks long. Among rheumatic
diseases of the childhood period, JIA is the most frequent
disorder with a reported prevalence of 16 and 150 per
100,000 children [1].
The underlying mechanisms responsible for
pathophysiology of JIA still remain unclear and
poorly understood but seem to have both genetic and
environmental components [2]. The clinical spectrum
of the disease is mostly heterogeneous and shows a wide

clinical diversity. Therefore, the JIA classification was
based on clinical findings, family history, and laboratory
examination including rheumatoid factor (RF), antinuclear
antibodies (ANA), and HLA-B27. Juvenile idiopathic
arthritis is classified within seven subgroups based on
specific inclusion and exclusion criteria according to
ILAR (The International League of Associations for
Rheumatology) classification [3]. Treatment consists of
pharmacotherapy, physical therapy, and physiological
support. Various measures are used in activity evaluation
in JIA, the most widely used scale is JADAS (Juvenile
Arthritis Disease Activity Score). Activity criteria guide
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the treatment selection. The main goal of the treatment is
to achieve complete control of inflammation and control
the JIA activation [4,5].
L- Carnitine (β-hydroxy-γ-trimethylaminobutyric
acid) is widely supplied in diet, mainly in foods from
animal sources like red meat and milk. Carnitine can
also endogenously be synthesized from two essential
amino acids lysine and methionine [6]. In cases where
carbohydrate storage is depleted, homeostasis of cellular
energy metabolism essentially becomes dependent on
mitochondrial fatty acid β-oxidation [6,7]. Carnitine
plays an essential role in long-chain fatty acids’ (LCFAs)
mitochondrial β-oxidation, particularly in steps of
esterification and transport into mitochondria. In addition
to its pivotal role in energy metabolism, carnitine is
cytoprotective, neuroprotective, and neuromodulator. The
protective effect of carnitine against oxidative stress has
also been reported [8–10]. There is not sufficient data in the
medical literature to claim that chronic low-to-moderate
inflammation causes carnitine deficiency. However, in
chronic diseases accompanied by systemic inflammation
carnitine replacement resulted in amelioration in
inflammation biomarkers. Chronic inflammation
increases the release of inflammatory cytokines such
as interleukin-6 and tumor necrosis factor-a which are
responsible for the synthesis of systemic inflammation
markers such as C-reactive protein (CRP) and serum
amyloid A (SAA). In patients with chronic kidney disease
and cardiovascular diseases, which is one of the disorders
accompanied by inflammation, carnitine supplementation
has been found to be effective in reducing serum CRP and
SAA, two systemic inflammation markers. In conclusion,
it could be suggested that there is a clear relationship
between prolonged inflammation and carnitine deficiency
[11–13].
Carnitine deficiencies can be classified as primary
and secondary carnitine deficiency. Primary carnitine
deficiency (PCD) is an inherited metabolic disorder of
disturbed fatty acid oxidation [14]. Secondary carnitine
deficiency (SCD) can be relevant to some inherited
metabolic disorders, pharmacotherapy like valproate,
zidovudine, and pivampicillin [11–18]. Secondary
carnitine deficiency can also be associated with chronic
diseases such as kidney disease, cirrhosis, diabetes
mellitus, heart failure, and malabsorption [19–21].
Trauma, septicemia, and acute organ failure result in SCD
by increasing carnitine demand [22–24].
Juvenile idiopathic arthritis is a clinical entity that
mainly presents with autoinflammation in joints and
other tissues. Nonsteroidal antiinflammatory drugs,
methotrexate, intra-articular steroids are listed as
treatment options used to improve the inflammatory
process [25]. We hypothesized that SCD may be seen due

to the increased demand in JIA patients. In this study, we
aimed to determine plasma carnitine status in Turkish JIA
patients.
2. Material and method
2.1. Study design and population
Our study is a cross-sectional study that was conducted
with 114 JIA patients followed by the outpatient Pediatric
Rheumatology clinic of Cerrahpaşa Medical Faculty
Children’s Hospital. The diagnosis of JIA was made by a
pediatric rheumatologist using ILAR criteria. Exclusion
criteria were the absence of a definite diagnosis of JIA,
treatment with carnitine, and refusal to participate in the
study. Demographic and clinical data including age, sex,
age at diagnosis, family history (including consanguinity,
additionally affected siblings), classification of JIA, clinical
findings (fatigue, muscle pain-cramps etc.), therapeutic
agents, and response to medical treatment were recorded.
A detailed physical examination was performed on all
JIA patients. The JADAS measurement scale was used to
evaluate the activity of JIA patients [5]. An age-matched
group of 50 healthy individuals was included as a control
group. In order to exclude any cause that may lead to
inflammation, control group participants were selected
from the population without any chronic disease, drug
or substance use, and nutritional problems (obesity or
malnutrition). Participants with a recent history of an
acute illness or vaccination were also excluded from the
control group.
In both groups, a fasting blood sample was collected
for free carnitine (FC) and acylcarnitine (AC) esters by
quadripole electrospray tandem mass spectrometry (ESIMS/ MS). Samples consisted of capillary blood collected on
Whatman S&S 903 filter paper. The samples were dried at
room temperature. Relevant AC butyl esters were extracted
and derivatized from 1/3 inch dried blood samples and
analyzed according to a protocol previously described by
Schulze et al [22]. AC butyl esters were detected based on
mass/ion ratios using ESI-MS/ MS. An Agilent 1200 Series
Autosampler and Water Micromass Quattro LC Likrom™
tandem mass spectrometry were used for the analyzes. The
values of AC were checked using the screening function
for positive ions mod m/z 85 parents. Quantitative values
of signal intensities were calculated using Masslynx and
Neolynx software (Ver 4.1). Both signal intensities and
calculated concentrations were exported to spreadsheet
software where abnormal concentration tagging and
further analysis were performed [26,27].
The study protocol was designed according to the
principles of Ethical Guidelines for Biomedical Research
Involving Human Subjects as defined in the Declaration
of Helsinki and was approved by the Ethical Committee
of İstanbul University-Cerrahpaşa, Cerrahpaşa Medical
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Faculty (15.12.2020/83045809-604.01.02). All parents of
the patients included in the present study gave informed
consent.
2.2. Statistical analysis
Statistical analyses were performed using Statistical
Package for Social Sciences version 26.0 (SPSS Inc.,
Chicago, IL, USA). The mean and standard deviation were
used as descriptive statistics. Categorical variables were
expressed as numbers and percentages. A one-sample
t-test was carried out for the quantitative estimation of
acyl-carnitine analyses. Comparison between the groups
was carried out by independent sample t-test.
3. Results
One hundred fourteen patients with JIA were enrolled
in the study. Data concerning clinical and demographic
findings of the patients are shown in Table 1. Free
carnitine and acyl-carnitine analyses in spot dried
blood samples with ESI-MS/MS were performed in all
patients. Evaluation of the acyl-carnitine profile revealed
statistically increased levels of free carnitine, C14, C14:2,
C16, C16-OH, and C18 carnitine (p < 0.0001, p < 0.0001,
p < 0.001, p < 0.001, and p = 0.011 respectively), while C2,
C3, C4, C6, C8, C10, C10:1, C10:2, C3DC, C4DC, C5DC,
C4-OH, and C18:1-OH carnitine levels were lower (p <
0.001) in JIA patients in comparison the control group.
Total acyl-carnitine levels (p < 0.001) and acyl-carnitine
to free carnitine ratio (p < 0.001) were also lower in JIA
patients than in the control group. Table 2 shows the acylcarnitine profile of both groups.
In terms of pharmacotherapy, 95 patients were under
antiinflammatory treatment and 19 were not receiving
any treatment agent. Fourteen of 95 patients were using
a combination of three antiinflammatory drugs (either
etanercept, adalimumab, or anakinra was combined with
methotrexate and steroid), 41 were using a combination of
two antiinflammatory drugs (combination of etanercept,
methotrexate, and steroid) and 40 were using one type
of medication. No statistical difference in plasma FC and
AC levels was detected between groups according to the
treatment modality. On the other hand, FC levels were
significantly higher in patients using antiinflammatory
treatment than those without any treatment (48.05 ± 13.36
μmol/L, 43.18 ± 7.96 μmol/L, respectively) (p = 0.004).
4. Discussion
In this study, we evaluated the plasma carnitine status
in patients diagnosed with JIA by using tandem mass
spectrometry. Several studies reported the possible impact
of inflammation resulting in carnitine deficiency [23,24].
However, it is the first study mentioning the carnitine
status in JIA in the medical literature.
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Table 1. Demographic and clinic characteristics of JIA patients
and control subjects.
Variables

Patients

Controls

Sex (male/female)

50/64

23/27

Age (months)

129.8 ± 53.6

129.67 ± 51.25

Consanguinity

59/114 (51.7%)

JIA Subtypes
Oligoarticular JIA

55/114 (48.2%)

Polyarticular JIA

43/114 (37.7%)

Enthesitis related JIA

10/114 (8.7%)

Systemic JIA

6/114 (5.2%)

Responsive to medication 110/114 (96.4%)
Fatigue

33/114 (28.9%)

Carnitine deficiency and/or a decrease in plasmafree carnitine levels were not detected in children with
JIA compared to the healthy control group in our study.
On the contrary, free carnitine, myristoylcarnitine (C14),
tetradecenoylcarnitine
(C14:1),
palmitoylcarnitine
(C16),
3-hydroxypalmitoylcarnitine
(C16-OH),
octadecanoylcarnitine (C18) levels were prone to be
elevated in children with JIA. In JIA patients C2 (Acetyl-),
C3 (Propionyl-), C4 (Butyryl-), C6 (Hexanoyl-), C8
(Octanoyl-), C10 (Decanoyl-), C10:1 (Decenoyl-),
C10:2 (Decadienoyl-), C3DC (Malonyl-), C4DC
(Methylmalonyl-), C5DC (Glutaryl-), C4-OH (3-Hydroxy
butyryl), and C18:1-OH (3-Hydroxy octadecenoyl-)
carnitine levels were lower in comparison to the control
subjects. On the other hand, total acylcarnitine levels and
acyl to free carnitine ratio were also found to be lower in
JIA patients. Studies suggest that an acyl/free carnitine
ratio above 0.4 is a supportive finding for carnitine
deficiency [28]. In our study, neither JIA patients nor
control subjects have high acyl/free carnitine ratio. It is
interesting that JIA patients had lower total acylcarnitine
levels, despite the high plasma levels of free carnitine and
long-chain acyl-carnitines. The above-mentioned changes
in carnitine homeostasis were suggested to be relevant
with possible impairment of peripheral carnitine usage
and mitochondrial energy metabolism in some individuals
with JIA.
Pharmacological treatment of JIA consists of several
options. Nonsteroidal antiinflammatory drugs (NSAIDs),
steroids, and intra-articular injections with triamcinolone
hexacetonide can be mentioned as first-line therapeutic
agents. Methotrexate is a second-line agent for
persistent arthritis. Several biologic agents are used in
drug-resistant JIA, including etanercept (TNF-soluble
receptor), Adalimumab (humanised anti-TNF antibody),
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Table 2. Free carnitine and acyl-carnitine levels of JIA patients and control subjects.
JIA patients (µmol/L)

Control subjects (µmol/L)

p

46.7671 ± 11.8631

33.0550 ± 7.8001

0.000

C2

5.7534 ± 2.6138

15.2324 ± 4.5400

0.000

C3

1.0382 ± 0.4174

1.8066 ± 0.8142

0.000

C4

0.1556 ± 0.0633

0.2156 ± 0.0774

0.000

C5

0.1094 ± 0.0357

0.1056 ± 0.0305

0.511

C5:1

0.0155 ± 0.0073

0.0188 ± 0.0084

0.380

C6

0.0451 ± 0.0133

0.0638 ± 0.0207

0.000

C8

0.0625 ± 0.0280

0.0886 ± 0.0437

0.000

C10

0.1010 ± 0.0505

0.1364 ± 0.0715

0.000

C10:1

0.0890 ± 0.0383

0.1290 ± 0.0591

0.000

C10:2

0.0175 ± 0.0079

0.0216 ± 0.0084

0.004

C14

0.1148 ± 0.0390

0.0862 ± 0.0250

0.000

C14:1

0.0587 ± 0.0231

0.0640 ± 0.0279

0.214

C14:2

0.0273 ± 0.0124

0.0228 ± 0.0127

0.040

C16

0.9424 ± 0.3137

0.7810 ± 0.2147

0.001

C16:1

0.0427 ± 0.0189

0.0444 ± 0.0166

0.578

C18

0.5726 ± 0.1955

0.4918 ± 0.1584

0.011

C18:1

0.8191 ± 0.2685

0.7662 ± 0.2188

0.225

C18:2

0.3501 ± 0.1383

0.3294 ± 0.0921

0.337

C3DC

0.0300 ± 0.0128

0.0414 ± 0.0226

0.000

C4DC

0.2794 ± 0.0956

0.4268 ± 0.1497

0.000

C5DC

0.0266 ± 0.0101

0.0424 ± 0.0191

0.000

C4-OH

0.0399 ± 0.0156

0.0760 ± 0.0472

0.000

C5-OH

0.1986 ± 0.0957

0.2180 ± 0.0772

0.211

C16-OH

0.0224 ± 0.0098

0.0170 ± 0.0067

0.001

C18:1-OH

0.0117 ± 0.0048

0.0140 ± 0.0057

0.011

C18:2-OH

0.0126 ± 0.0079

0.0110 ± 0.0070

0.235

Total acyl-carnitine

5.1828 ± 1.2495

6.0280 ± 1.3345

0.000

Free carnitine
Short-chain acyl-carnitines

Medium-chain acyl-carnitines

Long-chain acyl-carnitines

Acyl-carnitine esters derived from dicarboxylic acids

Acyl-carnitine esters derived from hydroxylated acids

Values are mean ± SD.

Abatacept (T-cell co-stimulation inhibitor), Anakinra
(IL-1 receptor antagonist), Canakinumab (Humanised
anti-IL-1 antibody) [25]. The main goal of treatment is to
control the inflammatory process. In our study, most of
the patients were receiving antiinflammatory treatment;
only four patients were refractory to treatment and 19
patients had not been receiving any medical treatment.
Good control of autoinflammation by pharmacotherapy

might have led to a lower need for carnitine in JIA
patients. On the other hand, patients who received
antiinflammatory treatment had higher levels of free
carnitine than those who did not. These results may also
indicate an impairment of long-chain fatty acid oxidation
and free carnitine consumption by the antiinflammatory
treatment. Also, another reason for the high carnitine
levels in patients receiving antiinflammatory therapy may
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also be the correction of increased carnitine consumption
triggered by inflammation with treatment.
The study group in our study was relatively small but
included a variety of combinations in which therapeutic
agents including etanercept, methotrexate, or steroids (46,
52, and 54 patients respectively) did not cause carnitine
deficiency. Among 114 patients, 33 patients had complaints
of fatigue, which may be associated with impaired energy
metabolism. Elevated free carnitine levels in JIA patients
have also been associated with insidious skeletal damage.
This study has some limitations. Most of the JIA
patients received antiinflammatory treatment during the
study. Antiinflammatory treatment may affect carnitine
levels. In addition, the nutritional status of the JIA patients
was not determined, especially regarding appropriate meat
consumption.
In conclusion, we did not find secondary carnitine
deficiency in JIA patients in this study, therefore
carnitine supplementation is not recommended in

all JIA patients. In contrast, alterations in free and
acyl-carnitine levels were found in JIA patients.
Therefore, impaired mitochondrial fatty acid oxidation
could be a secondary problem in JIA patients.
Further studies on screening carnitine status and fatty
acid oxidation in JIA patients are warranted, especially
screening carnitine status before and after treatment with
antiinflammatory medications will prevent the actual
carnitine status of JIA patients and the underlying factors
that influence energy metabolism.
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